Compare FAMI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAMI | ALZN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 9.0M |
| IPO Year | 2018 | 2021 |
| Metric | FAMI | ALZN |
|---|---|---|
| Price | $1.48 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 5.8K | ★ 97.4K |
| Earning Date | 01-26-2026 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,831,754.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $1.88 |
| 52 Week High | $7.07 | $12.06 |
| Indicator | FAMI | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 49.18 |
| Support Level | $1.45 | $2.03 |
| Resistance Level | $1.54 | $2.31 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 65.09 | 72.34 |
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.